Bill Text: NJ A4030 | 2016-2017 | Regular Session | Introduced
Bill Title: Permits pharmacists to dispense self-administered hormonal contraceptives pursuant to a standing order, in accordance with protocols established by Board of Pharmacy and Board of Medical Examiners.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2016-06-30 - Introduced, Referred to Assembly Health and Senior Services Committee [A4030 Detail]
Download: New_Jersey-2016-A4030-Introduced.html
Sponsored by:
Assemblyman DECLAN J. O'SCANLON, JR.
District 13 (Monmouth)
SYNOPSIS
Permits pharmacists to dispense self-administered hormonal contraceptives pursuant to a standing order, in accordance with protocols established by Board of Pharmacy and Board of Medical Examiners.
CURRENT VERSION OF TEXT
As introduced.
An Act concerning contraceptives and supplementing P.L.2003, c.280.
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. a. Notwithstanding any other law to the contrary, a pharmacist may furnish self-administered hormonal contraceptives to a patient, in accordance with standardized procedures and protocols to be jointly developed and approved by the Board of Pharmacy and the State Board of Medical Examiners, in consultation with the American Congress of Obstetricians and Gynecologists, the New Jersey Pharmacists Association, and other appropriate entities, and in accordance with the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.) and the provisions of this subsection.
b. At a minimum, the standardized procedures and protocols adopted under this subsection shall:
(1) provide for the issuance of a standing order authorizing pharmacists in this State to furnish self-administered hormonal contraceptives to patients without an individual prescription;
(2) identify the self-administered hormonal contraceptives that a pharmacist will be authorized to furnish to patients pursuant to the standing order;
(3) require a pharmacist to make clinical decisions that are free from any financial influence imposed by insurance providers, contraceptive product manufacturers, and other parties having a financial interest in the disbursement or non-disbursement of self-administered hormonal contraceptives;
(4) require a patient, prior to obtaining a self-administered hormonal contraceptive pursuant to this section, to use a self-screening tool that will identify patient risk factors for the use of self-administered hormonal contraceptives, based on the current United States Medical Eligibility Criteria for Contraceptive Use (US MEC) developed by the federal Centers for Disease Control and Prevention;
(5) require a pharmacist to offer to provide counseling to a patient about other forms of contraception that have been approved by the federal Food and Drug Administration, and, if the patient accepts the offer for counseling, require the pharmacist to provide the patient with specific and appropriate information about such other forms of contraception, based on the results of the self-screening tool administered pursuant to paragraph (4) of this subsection; and
(6) require a pharmacist, upon furnishing a self-administered hormonal contraceptive to a patient, or upon determining that a self-administered hormonal contraceptive is not recommended, to refer the patient to the patient's primary care provider, or, if the patient does not have a primary care provider, to an appropriate and nearby medical clinic.
c. The Board of Pharmacy and the Board of Medical Examiners are both authorized to ensure compliance with the provisions of this section, and each board is specifically charged with the enforcement of this section as applied to its respective licensees.
d. As used in this section, "self-administered hormonal contraceptive" means any oral, transdermal, or vaginal contraceptive product, including, but not limited to, birth control pills, vaginal rings, and diaphragms.
e. Nothing in this section shall be deemed to expand the authority of a pharmacist to prescribe any prescription medication.
2. This act shall take effect on the first day of the fourth month next following the date of enactment, except that the Board of Pharmacy and the State Board of Medical Examiners may take any administrative action in advance thereof as shall be necessary for the implementation of this act.
STATEMENT
This bill would permit pharmacists to furnish self-administered hormonal contraceptives to patients without an individual prescription, pursuant to procedures and protocols that are to be jointly adopted, pursuant to the "Administrative Procedure Act," by the Board of Pharmacy (board) and the State Board of Medical Examiners (BME), in consultation with the American Congress of Obstetricians and Gynecologists, the New Jersey Pharmacists Association, and other appropriate entities. Self-administered hormonal contraceptives are defined to mean any oral, transdermal, or vaginal contraceptive product, including, but not limited to, birth control pills, vaginal rings, and diaphragms.
The bill would require the procedures and protocols established by the board and BME to: (1) provide for the issuance of a standing order authorizing pharmacists in this State to furnish self-administered hormonal contraceptives to patients without an individual prescription; (2) identify the self-administered hormonal contraceptives that a pharmacist will be authorized to furnish to patients pursuant to the standing order; (3) require a pharmacist to make clinical decisions that are free from any financial influence imposed by insurance providers, contraceptive product manufacturers, and other parties having a financial interest in the disbursement or non-disbursement of self-administered hormonal contraceptives; (4) require a patient, prior to obtaining a self-administered hormonal contraceptive, to use a self-screening tool that will identify patient risk factors for the use of self-administered hormonal contraceptives, based on the current United States Medical Eligibility Criteria for Contraceptive Use (US MEC) developed by the federal Centers for Disease Control and Prevention; (5) require a pharmacist to offer to provide counseling to a patient about other forms of contraception that have been approved by the federal Food and Drug Administration, and, if the patient accepts the offer for counseling, require the pharmacist to provide the patient with specific and appropriate information about such other forms of contraception, based on the results of the self-screening tool; and (6) require a pharmacist, upon furnishing a self-administered hormonal contraceptive to a patient, or upon determining that a self-administered hormonal contraceptive is not recommended, to refer the patient to the patient's primary care provider, or, if the patient does not have a primary care provider, to an appropriate and nearby medical clinic.
The board and the BME would both be authorized to ensure compliance with these provisions, and each board, moreover, would be specifically charged with the enforcement of these procedures and protocols, as applied to the board's respective licensees.
The bill would specify that nothing in its provisions may be deemed to expand the authority of a pharmacist to prescribe prescription medications.
